5 Key Takeaways

• 1

  Renee Aguiar-Lucander joined Hansa Biopharma as CEO to recapitalize and turn the business around, achieving a significant Phase 3 study result.

• 2

  The Phase 3 study's high statistical significance (p < 0.0001) enabled Hansa to file a Biologics License Application with the FDA.

• 3

  Aguiar-Lucander emphasizes the need for timely clinical trials and improved oversight of contract research organizations.

• 4

  She advocates for reducing regulatory demands for randomized trials in early phases for rare diseases, favoring real-world evidence.

• 5

  Aguiar-Lucander predicts that in 10 years, drug development will see reduced regulatory review times and increased use of AI and real-world evidence.